Extended Data Fig. 9: Effects of ABT-263 on gene expression, blood tests, liver enzymes, metabolites, and lipids.

(a) Relative Cdkn2a mRNA transcript levels of BMDMs from CETP-APOE* Leiden mice crossed on different three backgrounds. Asterisks represent the p-value of ANOVA ≥ 0.05 (ns), <0.05 (✱), <0.01 (✱✱), <0.001 (✱✱✱), <0.0001 (✱✱✱✱). (b-d) Serum metabolite, serum lipid levels, and serum liver enzymes related to pathology MASH mice. ND was observed outside blood glucose. Asterisks represent the p-value of t-test ≥0.05 (ns), <0.05 (✱), <0.01 (✱✱), <0.001 (✱✱✱), <0.0001 (✱✱✱✱). (e) Relative mRNA transcript levels for inflammatory genes in bulk visceral adipose (VAT) and kidney samples. P-value represents the results of the t-test. (f) Bulk-RNAseq of the M1 and M2 genes in response to the senolytic drug, ABT-263. Scale bar represents Log2[TPM + 1] expression on a z-score axis. N = 6 Vehicle, and N = 5 ABT-263 treated mice used in this experiment. (g) Pathology graded histology reports for fibrosis on 5-6 MASH mice with and without ABT-263. (h) Fold change differences of normalized lipid abundance (nmol lipid per mg liver) for all lipid species via shotgun lipidomics (LC-MS/MS) relative to vehicle. Asterisks represent the p-value of t-test ≥0.05 (ns), <0.05 (✱), <0.01 (✱✱), <0.001 (✱✱✱), <0.0001 (✱✱✱✱).